HomeComparePROCF vs KMB

PROCF vs KMB: Dividend Comparison 2026

PROCF yields 1818.18% · KMB yields 5.25%● Live data

vsPost on X →
After 10 years · $10,000 invested · DRIP enabled
🏆 PROCF wins by $4103414683.79M in total portfolio value
10 years
PROCF
PROCF
● Live price
1818.18%
Share price
$0.11
Annual div
$2.00
5Y div CAGR
0%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$4103414683.84M
Annual income
$3,702,796,788,756,407.00
Full PROCF calculator →
KMB
KMB
● Live price
5.25%
Share price
$96.47
Annual div
$5.06
5Y div CAGR
17%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$45.9K
Annual income
$5,211.33
Full KMB calculator →

Portfolio growth — PROCF vs KMB

📍 PROCF pulled ahead of the other in Year 1

Annual dividend income

🛡️

Recession Test — Did They Cut Dividends?

How each stock treated shareholders during the 3 biggest crises of the last 20 years

Crisis PeriodPROCFKMB
2008–2009
GFC
— No data— No data
2020 Q1–Q2
COVID
— No data— No data
2022 Q4
Rate Hike
— No data— No data
Based on dividend payment history. "Increased" = dividend grew during crisis. "Maintained" = held within 3%. "Cut" = reduced by more than 3%.
📅

Dividend Calendar Overlap

Combined, PROCF + KMB cover 0 of 12 monthsgood coverage

Jan
Feb
Mar
Apr
May
Jun
Jul
Aug
Sep
Oct
Nov
Dec
PROCF pays
KMB pays
Both pay
Neither
💰

Tax Bracket Optimizer

Which stock is actually better after tax? Adjust your rate to find out.

PROCF
Annual income on $10K today (after 15% tax)
$154,545.45/yr
After 10yr DRIP, annual income (after tax)
$3,147,377,270,442,946.00/yr
KMB
Annual income on $10K today (after 15% tax)
$445.84/yr
After 10yr DRIP, annual income (after tax)
$4,429.63/yr
At 15% tax rate, PROCF beats the other by $3,147,377,270,438,516.50/year in after-tax income after 10 years on $10,000
⚖️

Lazy Portfolio Split Optimizer

What's the optimal mix of PROCF + KMB for your $10,000?

PROCF: 50%KMB: 50%
100% KMB50/50100% PROCF
Portfolio after 10yr
$2051707341.94M
Annual income
$1,851,398,394,380,809.20/yr
Blended yield
90.24%
📊

Analyst Conviction Gap

Where Wall Street is most bullish on KMB right now

PROCF
No analyst data
Altman Z
0.4
Piotroski
6/9
KMB
Analyst Ratings
9
Buy
19
Hold
3
Sell
Consensus: Hold
Price Target
$123.00
+27.5% upside vs current
Range: $102.00 — $162.00
Altman Z
3.4
Piotroski
7/9
Analyst ratings via FMP. Altman Z-Score: >3.0 safe, 1.81–3.0 grey zone, <1.81 distress. Piotroski: 7–9 strong, 0–3 weak.
🏛️

Copy Congress — What Are Politicians Buying?

Senate & House STOCK Act disclosures (last 90 days)

PROCF buys
0
KMB buys
0
No recent congressional trades found for PROCF or KMB in the last 90 days.
STOCK Act mandates disclosure within 45 days of transaction. Data via FMP.Full tracker →
MetricPROCFKMB
Forward yield1818.18%5.25%
Annual dividend / share$2.00$5.06
Payout ratio50%50%
1-year div growth0%0%
5-year div CAGR0%17%
Portfolio after 10y$4103414683.84M$45.9K
Annual income after 10y$3,702,796,788,756,407.00$5,211.33
Total dividends collected$4074760433.31M$21.5K
Payment frequencyquarterlyquarterly
SectorStockConsumer Staples

Year-by-year: PROCF vs KMB ($10,000, DRIP)

YearPROCF PortfolioPROCF Income/yrKMB PortfolioKMB Income/yrGap
1← crossover$192,518$181,818.18$11,314$613.68+$181.2KPROCF
2$3,477,331$3,271,336.99$12,865$759.19+$3.46MPROCF
3$58,943,217$55,222,471.89$14,709$943.96+$58.93MPROCF
4$937,891,469$874,822,227.57$16,919$1,180.17+$937.87MPROCF
5$14,012,869,532$13,009,325,660.38$19,588$1,484.33+$14012.85MPROCF
6$196,647,994,247$181,654,223,846.76$22,838$1,879.06+$196647.97MPROCF
7$2,592,865,386,485$2,382,452,032,641.56$26,832$2,395.60+$2592865.36MPROCF
8$32,132,661,421,271$29,358,295,457,731.54$31,788$3,077.63+$32132661.39MPROCF
9$374,409,247,740,494$340,027,300,019,734.44$38,000$3,986.82+$374409247.70MPROCF
10$4,103,414,683,838,736$3,702,796,788,756,407.00$45,872$5,211.33+$4103414683.79MPROCF

PROCF vs KMB: Complete Analysis 2026

PROCFStock

Procaps Group S.A. develops, produces, and markets pharmaceutical solutions worldwide. The company formulates, manufactures, and markets branded prescription drugs in various therapeutic areas, including feminine care products, pain relief, skin care, digestive health, growth and development, cardiology, vision care, central nervous system, and respiratory. It also provides drugs for hospital use, such as antibiotic, blood clot, personal protective equipment, immunosuppressant, oncology, and analgesics products. In addition, the company offers over-the-counter (OTC) consumer healthcare products through a portfolio on approximately eight therapeutic areas, including gastrointestinal, skin care, cough and cold, analgesics, urological, vitamins, minerals, and supplements in the categories of antibiotics, anti-infective, anti-parasitic, cardiovascular, feminine care, cutaneous antimycotic, pain killers, gastro intestinal, hormonals, metabolic, endocrine, nervous system, ophthalmic, osteoarticular, respiratory, diet supplements, and vitamins and minerals. Further, it provides blood glucose meters, telemonitoring products, oral anti-diabetics products, cosmeceuticals, insulin delivery systems, and other diabetes solutions; and contract drug development and manufacturing services to third party pharmaceutical companies, specializing in soft gelatin capsule technologies. The company was founded in 1977 and is based in Luxembourg, Luxembourg.

Full PROCF Calculator →

KMBConsumer Staples

Kimberly-Clark Corporation, together with its subsidiaries, manufactures and markets personal care and consumer tissue products worldwide. It operates through three segments: Personal Care, Consumer Tissue, and K-C Professional. The Personal Care segment offers disposable diapers, swimpants, training and youth pants, baby wipes, feminine and incontinence care products, and other related products under the Huggies, Pull-Ups, Little Swimmers, GoodNites, DryNites, Sweety, Kotex, U by Kotex, Intimus, Depend, Plenitud, Softex, Poise, and other brand names. The Consumer Tissue segment provides facial and bathroom tissues, paper towels, napkins, and related products under the Kleenex, Scott, Cottonelle, Viva, Andrex, Scottex, Neve, and other brand names. The K-C Professional segment offers wipers, tissues, towels, apparel, soaps, and sanitizers under the Kleenex, Scott, WypAll, Kimtech, and KleenGuard brands. The company sells household use products directly to supermarkets, mass merchandisers, drugstores, warehouse clubs, variety and department stores, and other retail outlets, as well as through other distributors and e-commerce; and away-from-home use products directly to manufacturing, lodging, office building, food service, and public facilities, as well as through distributors and e-commerce. Kimberly-Clark Corporation was founded in 1872 and is headquartered in Dallas, Texas.

Full KMB Calculator →
📬

Get this PROCF vs KMB comparison by email

Save your analysis + weekly dividend insights. Free forever.

More comparisons

PROCF vs SCHDPROCF vs JEPIPROCF vs OPROCF vs KOPROCF vs MAIN

⚠️ Educational purposes only. Not financial advice. Congressional trades sourced from SEC STOCK Act filings via FMP. Past performance does not guarantee future results.